References
- Leo M E, Bilhartz D L, Bergstrahl E J, Oesterling J E. Prostate specific antigen in hormonally treated stage D2 prostate cancer; is it always an accurate indicator of disease status?. J Urol 1991; 145: 802–6
- Fosså S D, Wéhre H, Paus E. The prognostic significance of prostate specific antigen in metastatic hormone-resistant prostate cancer. Br J Cancer 1992; 66: 181–4
- Hussain M, Wolf M, Marshall E, Crawford E D, Eisenberger M. Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy for hormone-refractory prostate cancer: a Southwest Oncology Group Report. J Clin Oncol 1994; 12: 1868–75
- Taylor C D, Elson P, Trump D I. Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol 1993; 11: 2167–72
- Akakura K, Bruchovsky N, Goldenberg S L, Rennie P S, Buckely A R, Sullivan L D. Effects of intermittent androgen suppression on androgen-dependent tumors. Cancer 1993; 71: 2782–90